CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Chronic Kidney Disease and Coronary Artery Disease In-Hospital Costs and Costs of Complications of Chronic Total Occlusion Angioplasty Insights From the OPEN-CTO Registry Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review Drug-eluting balloons in coronary interventions: the quiet revolution? Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine Diagnostic performance of stress perfusion cardiac magnetic resonance for the detection of coronary artery disease: A systematic review and meta-analysis Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns

Original Research2021 Jan 13.

JOURNAL:Circulation. Article Link

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial

GG Schwartz, PG Steg, ODYSSEY OUTCOMES Committees and Investigators et al. Keywords: PCSK9 inhibition; lipoprotein(a)

Full Text PDF